UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Re-evaluating Subsequent Treatment Options in Non-small Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors

Clinical oncology (Royal College of Radiologists (Great Britain)), 2022-07, Vol.34 (7), p.469-471

Greystoke, A.

2022

Volltextzugriff (PDF)

Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

Annals of oncology, 2023-01, Vol.34 (1), p.48-60

2023

Volltextzugriff (PDF)

Cardiopulmonary fitness before and after neoadjuvant chemotherapy in patients with oesophagogastric cancer

British journal of surgery, 2018-06, Vol.105 (7), p.900-906

2018

Volltextzugriff (PDF)

Biomarker method validation in anticancer drug development

British journal of pharmacology, 2008-02, Vol.153 (4), p.646-656

2008

Volltextzugriff (PDF)

Social determinants of health inequalities in early phase clinical trials in Northern England

British journal of cancer, 2024-09, Vol.131 (4), p.685-691

2024

Volltextzugriff (PDF)

TARGET National: A UK-wide Liquid-based Molecular Profiling Programme: On Behalf of the TARGET National Consortium

Clinical oncology (Royal College of Radiologists (Great Britain)), 2023-01, Vol.35 (1), p.33-37

2023

Volltextzugriff (PDF)

Comparison of the effects of FLOT and ECX chemotherapy for oesophagogastric adenocarcinoma on cardiopulmonary reserve

British journal of surgery, 2021-10, Vol.108 (10), p.e328-e329

2021

Volltextzugriff (PDF)

Metastatic Brain Disease from Non-small Cell Lung Cancer – Getting Back to the Drawing Board

Clinical oncology (Royal College of Radiologists (Great Britain)), 2018-03, Vol.30 (3), p.137-143

2018

Volltextzugriff (PDF)

Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders

Journal of cancer research and clinical oncology, 2023-12, Vol.149 (18), p.16355-16363

2023

Volltextzugriff (PDF)

The UK at the Forefront of Innovative Drug–Radiotherapy Combination Clinical Trials: Introducing the CONCORDE Platform

Clinical oncology (Royal College of Radiologists (Great Britain)), 2020-06, Vol.32 (6), p.358-362

2020

Volltextzugriff (PDF)

Hypofractionated Concurrent Chemoradiation in Stage III Non-small Cell Lung Cancer: Does Planning Target Volume Size Correlate With Prognosis?

Clinical oncology (Royal College of Radiologists (Great Britain)), 2019-06, Vol.31 (6), p.402-403

2019

Volltextzugriff (PDF)

86: The impact of age, performance status and co-morbidities in determining treatment options in elderly patients with non-small cell lung cancer (NSCLC) in Newcastle upon Tyne NHS trust (NUTH)

Lung cancer (Amsterdam, Netherlands), 2015, Vol.87, p.S33-S34

2015

Volltextzugriff (PDF)

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

British journal of cancer, 2011-03, Vol.104 (5), p.750-755

2011

Volltextzugriff (PDF)

Mode of Histological Diagnosis in Patients With Non-small Cell Lung Cancer Treated With Chemoradiotherapy: Its Prognostic Implication, Especially in Light of the European Durvalumab Licence?

Clinical oncology (Royal College of Radiologists (Great Britain)), 2019-09, Vol.31 (9), p.671-671

2019

Volltextzugriff (PDF)

107 Performance status, not age, influences decision-to-treat in non small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2016, Vol.91, p.S38-S38

2016

Volltextzugriff (PDF)

Hypofractionated Concomitant Chemoradiation in Inoperable Locally Advanced Non-small Cell Lung Cancer: A Report on 100 Patients and a Systematic Review

Clinical oncology (Royal College of Radiologists (Great Britain)), 2019-02, Vol.31 (2), p.e1-e10

2019

Volltextzugriff (PDF)

Learning from toxicity patterns in phase I trials during the era of mechanism targeted agents

Annals of oncology, 2012-08, Vol.23 (8), p.1934-1936

2012

Volltextzugriff (PDF)

Brigatinib experience on the ALK project

Annals of oncology, 2019-04, Vol.30, p.ii53-ii53

2019

Volltextzugriff (PDF)

How Many Diseases Are Colorectal Cancer?

Gastroenterology research and practice, 2012-01, Vol.2012 (2012), p.1-12

2012

Volltextzugriff (PDF)

A feasibility study to investigate the utility of a home-based exercise intervention during and after neo-adjuvant chemotherapy for oesophago-gastric cancer-the ChemoFit study protocol

Pilot and feasibility studies, 2020-04, Vol.6 (1), p.50-50, Article 50

2020

Volltextzugriff (PDF)

Biomarkers of apoptosis

British journal of cancer, 2008-09, Vol.99 (6), p.841-846

2008

Volltextzugriff (PDF)

Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study

Annals of oncology, 2019-04, Vol.30, p.ii48-ii48

2019

Volltextzugriff (PDF)

Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC

Annals of oncology, 2018-11, Vol.29, p.ix151-ix152

2018

Volltextzugriff (PDF)

Implications for UK practice of the use of durvalumab in stage III NSCLC

Annals of oncology, 2019-04, Vol.30, p.ii36-ii36

2019

Volltextzugriff (PDF)

Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer

British journal of cancer, 2012-10, Vol.107 (9), p.1518-1524

2012

Volltextzugriff (PDF)

1 – 25 von 288

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(281)
Mit Volltextzugriff
(261)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(6)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

Re-evaluating Subsequent Treatment Options in Non-small Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors

Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

Cardiopulmonary fitness before and after neoadjuvant chemotherapy in patients with oesophagogastric cancer

Biomarker method validation in anticancer drug development

Social determinants of health inequalities in early phase clinical trials in Northern England

TARGET National: A UK-wide Liquid-based Molecular Profiling Programme: On Behalf of the TARGET National Consortium

Comparison of the effects of FLOT and ECX chemotherapy for oesophagogastric adenocarcinoma on cardiopulmonary reserve

Metastatic Brain Disease from Non-small Cell Lung Cancer – Getting Back to the Drawing Board

Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders

The UK at the Forefront of Innovative Drug–Radiotherapy Combination Clinical Trials: Introducing the CONCORDE Platform

Hypofractionated Concurrent Chemoradiation in Stage III Non-small Cell Lung Cancer: Does Planning Target Volume Size Correlate With Prognosis?

86: The impact of age, performance status and co-morbidities in determining treatment options in elderly patients with non-small cell lung cancer (NSCLC) in Newcastle upon Tyne NHS trust (NUTH)

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

Mode of Histological Diagnosis in Patients With Non-small Cell Lung Cancer Treated With Chemoradiotherapy: Its Prognostic Implication, Especially in Light of the European Durvalumab Licence?

107 Performance status, not age, influences decision-to-treat in non small cell lung cancer (NSCLC)

Hypofractionated Concomitant Chemoradiation in Inoperable Locally Advanced Non-small Cell Lung Cancer: A Report on 100 Patients and a Systematic Review

Learning from toxicity patterns in phase I trials during the era of mechanism targeted agents

Brigatinib experience on the ALK project

How Many Diseases Are Colorectal Cancer?

A feasibility study to investigate the utility of a home-based exercise intervention during and after neo-adjuvant chemotherapy for oesophago-gastric cancer-the ChemoFit study protocol

Biomarkers of apoptosis

Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study

Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC

Implications for UK practice of the use of durvalumab in stage III NSCLC

Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer

Suchergebnisse filtern